AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01613794
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg od
Trial: NCT01071850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT00574067
Drug: Counseling +OTP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
Trial: NCT02291367
Drug: Cymbalta®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg capsule of Eli Lilly and Company
Trial: NCT01474187
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 625mg/m2,bid,d1-5,qw
Trial: NCT05917691
Drug: General anesthetic
RxNorm normalized name: General anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cases were required to have a documented general anesthesia anesthetic technique. Administered drugs were otherwise indeterminate under the current study design (observational study of a deidentified database).
Trial: NCT01514123
Drug: VGX-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VGX-100 will be administered by IV infusion once every week
Trial: NCT03062839
Drug: Melatonin 5 mg
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 5 mg taken 30 minutes before bed time
Trial: NCT04476186
Drug: KOH 10 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for local application
Trial: NCT02487082
Drug: Melatonin and Donepezil
RxNorm normalized name: donepezil and memantine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 weeks of active study medication in Group A during Phase 1 \& Phase 2. 5 weeks of active study medication in Group B during Phase 2.
Trial: NCT02812654
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75mg/m2 (cycle 1,2 and 3)
Trial: NCT00429624
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02159287
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 unit per hour continuous intravenous infusion of heparin sodium
Trial: NCT00496028
Drug: AZD0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04108832
Drug: TCM OA2
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usage: 3g twice daily
Trial: NCT04108832
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usage: 3g twice daily
Trial: NCT02218307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01859026
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as outlined in study arms.
Trial: NCT00638833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills
Trial: NCT02438696
Drug: BI 1060469, iFF, Test
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02438696
Drug: BI 1060469, TF2, Test
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02438696
Drug: BI 1060469, TF1, Reference
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00893451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally twice daily
Trial: NCT00442546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00095862
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01668823
Drug: photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo photodynamic therapy with HPPH
Trial: NCT02856087
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline infusion
Trial: NCT01263886
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution~Route of administration: intravenous
Trial: NCT03558035
Drug: Induction CT+ CRT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
Trial: NCT04219358
Drug: Vehicle Gel Base
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks.~Gel components: medium molecular weight chitosan, lactic acid 85% and water.
Trial: NCT04219358
Drug: Lip sunscreen 30 Sun Protector Factor (SPF)
RxNorm normalized name: Worm Protector 2X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply sunscreen on the lip 30 minutes every day before sun exposure. Protects against both UVA (ultraviolet A) and UVB (ultraviolet B rays).
Trial: NCT01530308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral dosage of 1mg twice-daily at 12am and 8 pm.
Trial: NCT03458143
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conscious sedation in TCI-mode
Trial: NCT01806610
Drug: BPS804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose BPS804 administration.
Trial: NCT01806610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose placebo administration.
Trial: NCT00130234
Drug: Xolair® (Omalizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02426541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
Trial: NCT00040690
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00040690
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00040690
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00040690
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00745134
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01198249
Drug: multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
Trial: NCT03868111
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
Trial: NCT03868111
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
Trial: NCT00472953
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target dose titration scheme, pre-prandial, inhalation.
Trial: NCT00865449
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
Trial: NCT00865449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given daily for 6 months to Peritoneal Dialysis Patients
Trial: NCT00930241
Drug: Advagraf®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advagraf® (one daily dose of Tacrolimus)
Trial: NCT00930241
Drug: Prograf®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prograf® (two daily doses of Tacrolimus)
Trial: NCT02397213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
Trial: NCT04403399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial placebo oral dose administered with monitoring over 4 hours, then total daily dose escalated over the next 2 days until final placebo BID dosing administered orally for the remaining 3 weeks.
Trial: NCT00172068
Drug: Zoledronic acid + Calcium/Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01769365
Drug: 7-day quadruple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
Trial: NCT01769365
Drug: 10-day sequential therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
Trial: NCT01769365
Drug: 7-day standard triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
Trial: NCT01011725
Drug: MK 0773
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks
Trial: NCT01011725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet b.i.d for 12 weeks
Trial: NCT04542694
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.~Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc.
Trial: NCT02672540
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-hour infusion of Normal Saline and Day 1 and Day 2
Trial: NCT00392457
Drug: gonadotropin releasing hormone (GnRH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
Trial: NCT02295813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006371
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01363011
Drug: E/C/F/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
Trial: NCT01363011
Drug: DRV
RxNorm normalized name: Urinal Male Drv RTLPC23201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV 800 mg tablet administered orally once daily
Trial: NCT01363011
Drug: NRTI
RxNorm normalized name: Nucleoside Reverse Transcriptase Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
Trial: NCT03653026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration
Trial: NCT01955512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT02156154
Drug: Intravenous Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03490916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Placebo
Trial: NCT02971722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml/bottle
Trial: NCT00003396
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01563458
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
Trial: NCT01270490
Drug: Interferon-gamma, Recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon 50 mcg/m2 to be administered three times per week during two weeks
Trial: NCT00625326
Drug: 50 µg/g Calcipotriene Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg/g Calcipotriene Ointment
Trial: NCT00625326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02575339
Drug: MLN0128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
Trial: NCT02575339
Drug: MLN0128 (RP2D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly.
Trial: NCT01473147
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 2 u bid sc.
Trial: NCT03527680
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily one capsule of placebo
Trial: NCT00111956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00935831
Drug: GSK1278863A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg, 150mg
Trial: NCT00935831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT04397289
Drug: Heparin and Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Low molecular weight heparin 5000U ih Q12h was given 24 hours after operation, 5 days after operation Rivaroxaban 10mg PO QD from 24 hours after operation, 30 days after operation
Trial: NCT03756883
Drug: Placebo Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active content
Trial: NCT04523246
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline, inactive control.
Trial: NCT02614833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
Trial: NCT02741154
Drug: induction with aromataze inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: letrozole 2.5mg once daily start in the first day of menses for 5days
Trial: NCT02741154
Drug: HMG
RxNorm normalized name: HMG-CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
Trial: NCT00760786
Drug: Intensive lipid lowering plus Omega3-fatty acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
Trial: NCT00760786
Drug: Moderate lipid lowering plus Omega3-fatty acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
Trial: NCT00760786
Drug: Intensive lipid lowering plus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 40mg qd
Trial: NCT00760786
Drug: Moderate lipid lowering plus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 10mg qd
Trial: NCT01483625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01228227
Drug: ROSUVASTATIN 40 mg
RxNorm normalized name: rosuvastatin 40 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: reload of rosuvastatin 40 mg before the procedure
Trial: NCT00271024
Drug: Placebo (for Naltrexone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Naltrexone tablet
Trial: NCT00432055
Drug: placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04170413
Drug: CeVUS
RxNorm normalized name: Cervus elaphus horn oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast enhanced voiding urosonography
Trial: NCT03566238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical in appearance to active drug (A4250).
Trial: NCT05667948
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: different treatments based on the molecular analysis
Trial: NCT04227041
Drug: Pyrotinib in combination with capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pyrotinib in combination with capecitabine
Trial: NCT01104428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
Trial: NCT01104428
Drug: ziying granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: granules, \<10years,10g,Three times a day,take orally \>10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
Trial: NCT00003862
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003862
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04030663
Drug: xlyocaine
RxNorm normalized name: Alocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
Trial: NCT01832402
Drug: Fentanyl Pectin Nasal Spray
RxNorm normalized name: fentanyl Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
Trial: NCT01832402
Drug: Placebo Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
Trial: NCT04812574
Drug: Hypertonic (10%) saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periurethral hypertonic saline (10%)
Trial: NCT03206151
Drug: CMAB009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for injection only
Trial: NCT00577148
Drug: Placebo (for Rimonabant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT01588535
Drug: benzocaine
RxNorm normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
Trial: NCT01588535
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo solution, five drops in affected ear canal each hour as needed
Trial: NCT02087917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.